The most played episodes among Podcast App listeners.

1. 1
   Number 1: PI3K Pathway Hyperglycemia

   Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well as the implications of which anti-diabetes medications are used in response is discussed. Review article: https://doi.org/10.1177/15347354211073163 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

   September 24, 2026·11min
   Play
2. 2
   Number 2: How to Read a Press Release and Drug Shortage Help

   Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from these? We read through two examples for just this purpose. Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet Possible Help with Drug Shortages: https://www.angelsforchange.org Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

   September 10, 2026·15min
   Play
3. 3
   Number 3: Paradigm and Daraxonrasib in NSCLC

   PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

   September 03, 2026·15min
   Play
4. 4
   Number 4: Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

   This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer 2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea. 3. The largest RCT in primary CNS lymphoma Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

   August 27, 2026·21min
   Play
5. 5
   Number 5: Iberdomide

   CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897 Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

   August 20, 2026·16min
   Play